EXTON, PA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Rheumatologists report high satisfaction with AbbVie’s Rinvoq (upadacitinib) following its recent approval in giant cell arteritis (GCA), with the majority citing anticipated efficacy, steroid-sparing benefits, and convenient oral administration as central drivers of adoption. Nearly all specialists are aware of the approval, and 40% have already prescribed Rinvoq for GCA patients, an early adoption curve that compares favorably with the brand’s prior launches i ...

Accessibility StatementSkip Navigation Allergan Aesthetics Global Medical Affairs Symposium on Skin Quality Multimodal MasteryA single- strategy treatment plan may not be enough to unlock the skin's full potential, and a multimodal approach is the focus of this year's medical symposium, 'Mastering Skin Quality - Integrating Aesthetic Modalities for Holistic Skin Quality Improvement' on Wednesday, 1 October at 2PM-4PM in Al Ameera Ballroom 2, Grand Hyatt Dubai. With 94% of people wanting to improve their fa ...

In the latest trading session, AbbVie (ABBV) closed at $219.99, marking a -1.18% move from the previous day. This change lagged the S&P 500's 0.29% loss on the day. Elsewhere, the Dow saw a downswing of 0.37%, while the tech-heavy Nasdaq depreciated by 0.34%. Heading into today, shares of the drugmaker had gained 6.84% over the past month, outpacing the Medical sector's loss of 0.33% and the S&P 500's gain of 3.08%.The upcoming earnings release of AbbVie will be of great interest to investors. The company's ...

The Dividend Kings posted a very nice gain of 3.26% in August, outpacing the SPDR S&P 500 ETF Trust ( SPY ) by a cool 1.21%. September, however, is not faring as well; SPY is up 2.9% throughI have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forward to sharing my thoughts with the Seeki ...

交易概述 - 公司与恒瑞医药签署独家许可协议 涉及前期付款1800万美元及最高10.93亿美元的监管与商业里程碑付款[1] - 协议涵盖在研乳腺癌和肺癌药物Trastuzumab Rezetecan（SHR-A1811）的开发和商业化权利[2] - 交易范围排除中国、美国、加拿大、欧洲、日本、俄罗斯及独联体地区 公司将在授权区域支付销售分成[4] 药物特性 - Trastuzumab Rezetecan为靶向HER2阳性癌症的新一代抗体药物偶联物（ADC）[2] - ADC技术通过抗体将化疗药物精准递送至癌细胞[2] - 该药物于2025年5月在中国获批治疗非小细胞肺癌 适用于无法手术或转移性经治患者[3] - 2025年8月获得美国FDA孤儿药认定 用于胃癌及胃食管结合部腺癌治疗[3] 商业战略 - 公司通过子公司Glenmark Specialty S.A.开展合作 持续扩展肿瘤学产品管线[2][5] - 重点布局复杂生物制剂领域 专注于高负担且服务不足市场的下一代疗法[5] - 2024年5月与BeOne达成癌症药物Tislelizumab和Zanubrutinib在印度市场的分销协议[6] - 2025年7月通过美国子公司IGI与艾伯维达成7亿美元血液癌症药物授权协议[6] 市场环境 - 印度市场已上市两款HER2阳性ADC药物：Zydus Cadila的Ujvira和阿斯利康-第一三共的Enhertu[3] - IGI与艾伯维交易包含最高12.3亿美元里程碑付款 创印度药企对外授权金额纪录[6][7] - 公司股价在公告当日收涨0.2% 报2,020.10卢比/股[8] 研发进展 - Trastuzumab Rezetecan目前处于多项临床试验推进阶段[3] - IGI研发管线包含ISB 2301等资产 处于实体瘤应用的发现阶段[7] - 公司采取"先独立研发至特定阶段 再选择自主或合作开发"的差异化策略[7]

智通财经APP获悉，9月23日，药品审评中心(CDE)网站显示，艾伯维(ABBV.US)的艾可瑞妥单抗注射液(epcoritamab)在华申报新适应症。根据优先审评进 展，本次申报的适应症为联合利妥昔单抗和来那度胺治疗复发或难治性滤泡性淋巴瘤(FL)成人患者。 艾可瑞妥单抗是Genmab利用其专有的DuoBody技术开发的一款IgG1双特异性抗体，可同时靶向T细胞上的CD3和B细胞上的CD20，诱导T细胞杀伤 CD20+细胞。 8月7日， 一项评估艾可瑞妥单抗联合利妥昔单抗+来那度胺对比利妥昔单抗+来那度胺方案，用于成人复发或难治性滤泡性淋巴瘤(R/R FL)患者的疗效与 安全性的III期研究(EPCORE FL-1研究)取得积极结果。预设中期分析显示，该研究已达到ORR和PFS双重主要终点。 艾可瑞妥单抗联合治疗组的ORR达95.7%(p<0.0001)，PFS风险比(HR)为0.21(p<0.0001)，疾病进展或死亡风险降低79%。美国FDA已受理艾可瑞妥单抗用于 该适应症的sBLA并授予优先审评资格，PDUFA日期为2025年11月30 日。 | 受理品种目录浏览 | 在审品种目录浏览 | | | | ...

Multimodal Approach to Skin Quality at AMWC, Dubai Accessibility StatementSkip Navigation IRVINE, Calif., Sept. 23, 2025 /PRNewswire/ --  Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the roll-out of SKINVIVE by JUVÉDERM in 35 additional markets this year bringing the total to 57 globally in 2025. This expansion underscores Allergan Aesthetics' global strategic commitment to enhancing skin quality worldwide. SKINVIVE is an advanced skincare solution for healthy-looking skin, delive ...

The stock has outperformed the broader market since its 2013 IPO, and can still do so over the long run.Strong dividend payers can be a stabilizing force in a well-diversified portfolio. That's because corporations that can consistently pay and raise their payouts over a long period are often relatively low-risk, well-established companies with robust underlying operations.Often, but not always. Some will stop dividend hikes or even suspend their programs altogether when trouble arises.So, dividend seekers ...

AbbVie Inc. (NYSE:ABBV) is one of the 15 Best Stocks to Invest in for Financial Stability. Piper Sandler Reiterates Its ‘Overweight’ Rating on AbbVie Inc. (ABBV) with a $231 PT On September 12, 2025, Piper Sandler reiterated its ‘Overweight’ rating on AbbVie Inc. (NYSE:ABBV) with a $231 price target. This comes after the company settled with abbreviated New Drug Application (ANDA) filers over Rinvoq. The agreement delays generic entry until April 2037, which is four years beyond the expiration of key co ...

Key Points AbbVie is a sector mainstay that had no fewer than 12 drugs with net sales above $1 billion last year. It also paid a generous dividend. 10 stocks we like better than AbbVie › It isn't easy to find a pharmaceutical company that has a strong product lineup and a robust pipeline, but also cranks out a generous dividend every quarter. I've been an AbbVie (NYSE: ABBV) bull for years, and especially these days, I think it's a bargain stock that can produce outsized returns for a long time to ...